Intellectual Property India Publishes Patent Application for 'RNAI Constructs For Inhibiting Ttr Expression And Methods Of Use Thereof' Filed by Amgen Inc.

MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202517066540 A) filed by Amgen Inc., Thousand Oaks, U.S.A., on July 11, for 'rnai constructs for inhibiting ttr expression and methods of use thereof.'

Inventor(s) include Rulifson, Ingrid; Meade, Bryan; Long, Jason C; and Murray, Justin K.

The application for the patent was published on July 25, under issue no. 30/2025.

According to the abstract released by the Intellectual Property India: "The disclosure relates to RNAi constructs, such as siRNA, for reducing expression of the TTR gene. Methods of using such RNAi constructs to treat or prevent cardiac disease, such as transthyretin-associated cardiomyopathy (ATTR-CM), are also described."

The patent application was internationally filed on Dec. 15, 2023, under International application No.PCT/US2023/084321.

Disclaimer: Curated by HT Syndication.